CA2600221C - Measuring range extension of chromatographic rapid tests - Google Patents
Measuring range extension of chromatographic rapid tests Download PDFInfo
- Publication number
- CA2600221C CA2600221C CA2600221A CA2600221A CA2600221C CA 2600221 C CA2600221 C CA 2600221C CA 2600221 A CA2600221 A CA 2600221A CA 2600221 A CA2600221 A CA 2600221A CA 2600221 C CA2600221 C CA 2600221C
- Authority
- CA
- Canada
- Prior art keywords
- analyte
- specific substance
- reaction time
- predetermined reaction
- signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000012360 testing method Methods 0.000 title claims description 53
- 239000012491 analyte Substances 0.000 claims abstract description 122
- 238000000034 method Methods 0.000 claims abstract description 46
- 230000035484 reaction time Effects 0.000 claims description 45
- 239000000126 substance Substances 0.000 claims description 37
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 238000001514 detection method Methods 0.000 claims description 14
- 102400001263 NT-proBNP Human genes 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 230000003287 optical effect Effects 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 102000004856 Lectins Human genes 0.000 claims description 2
- 108090001090 Lectins Proteins 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 230000008105 immune reaction Effects 0.000 claims description 2
- 239000002523 lectin Substances 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 230000005526 G1 to G0 transition Effects 0.000 claims 2
- 101800001904 NT-proBNP Proteins 0.000 claims 2
- 238000007705 chemical test Methods 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 7
- 239000003550 marker Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102100036836 Natriuretic peptides B Human genes 0.000 description 4
- 101710187802 Natriuretic peptides B Proteins 0.000 description 4
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
- 239000003154 D dimer Substances 0.000 description 3
- 102000036675 Myoglobin Human genes 0.000 description 3
- 108010062374 Myoglobin Proteins 0.000 description 3
- 102000004987 Troponin T Human genes 0.000 description 3
- 108090001108 Troponin T Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 108010052295 fibrin fragment D Proteins 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000012854 evaluation process Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002644 neurohormonal effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000007430 reference method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 108030001694 Pappalysin-1 Proteins 0.000 description 1
- 102000005819 Pregnancy-Associated Plasma Protein-A Human genes 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- -1 antibodies Proteins 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06019008.9 | 2006-09-11 | ||
| EP06019008A EP1909206A1 (de) | 2006-09-11 | 2006-09-11 | Messbereichserweiterung chromatografischer Schnellteste |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2600221A1 CA2600221A1 (en) | 2008-03-11 |
| CA2600221C true CA2600221C (en) | 2017-05-30 |
Family
ID=37696091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2600221A Expired - Fee Related CA2600221C (en) | 2006-09-11 | 2007-09-06 | Measuring range extension of chromatographic rapid tests |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080070234A1 (enExample) |
| EP (1) | EP1909206A1 (enExample) |
| JP (1) | JP4823178B2 (enExample) |
| CN (1) | CN101144810B (enExample) |
| CA (1) | CA2600221C (enExample) |
| ES (1) | ES2533467T3 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010017972A1 (en) * | 2008-08-13 | 2010-02-18 | Roche Diagnostics Gmbh | D-dimer, troponin, nt-probnp for pulmonary embolism |
| WO2014096184A1 (en) * | 2012-12-20 | 2014-06-26 | Roche Diagnostics Gmbh | Method for analyzing a sample of a body fluid |
| EP2936124B1 (en) * | 2012-12-20 | 2017-03-15 | Roche Diabetes Care GmbH | Methods for evaluating medical measurement curves |
| CN104714025B (zh) * | 2014-11-28 | 2017-05-17 | 威海纽普生物技术有限公司 | NT‑proBNP检测试剂盒及检测方法 |
| CN107505299A (zh) * | 2017-09-04 | 2017-12-22 | 中国人民解放军第三军医大学 | 一种从尿液中检测骨骼肌微损伤标志物肌红蛋白的方法 |
| KR20190076624A (ko) * | 2017-12-22 | 2019-07-02 | 삼성전자주식회사 | 검사 장치 및 그 제어방법 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2946850B2 (ja) * | 1991-06-30 | 1999-09-06 | 株式会社島津製作所 | 抗原抗体反応におけるプロゾーン判定方法及び分析方法 |
| FR2693213B1 (fr) | 1992-07-03 | 1994-08-05 | Kaysersberg Sa | Procede destine a diminuer l'interaction entre fibres dans un tissue et mise en óoeuvre de ce procede, notamment pour fabriquer des tissues multi-strates. |
| JPH0696697A (ja) | 1992-09-11 | 1994-04-08 | Hitachi Ltd | カラー陰極線管 |
| US5756362A (en) * | 1993-10-12 | 1998-05-26 | Cornell Research Foundation, Inc. | Liposome-enhanced immunoaggregation assay and test device |
| JPH0875740A (ja) * | 1994-08-31 | 1996-03-22 | Shimadzu Corp | 免疫比濁分析方法 |
| US6830731B1 (en) * | 1998-01-05 | 2004-12-14 | Biosite, Inc. | Immunoassay fluorometer |
| EP1151304B9 (de) * | 1999-01-29 | 2008-06-04 | Roche Diagnostics GmbH | VERFAHREN ZUM NACHWEIS VON N-TERMINALEM proBNP |
| JP3726082B2 (ja) * | 2000-12-26 | 2005-12-14 | 松下電器産業株式会社 | 特異結合分析方法およびそれに用いる特異結合分析装置 |
| EP1416276B1 (en) * | 2001-08-09 | 2007-03-07 | Matsushita Electric Industrial Co., Ltd. | Biosensors and measurement method |
| EP1361435A4 (en) * | 2001-09-28 | 2005-01-26 | Matsushita Electric Industrial Co Ltd | ANALYZER AND PROCESS FOR SPECIFIC BINDING |
| WO2003056312A1 (en) * | 2001-12-27 | 2003-07-10 | Arkray, Inc. | Concentration measuring method |
| ATE339687T1 (de) * | 2002-05-22 | 2006-10-15 | Sysmex Corp | Immunologische verfahren, vorrichtungen und reagenzien |
| AU2003302340B8 (en) * | 2002-12-24 | 2008-09-11 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| US20050250141A1 (en) * | 2004-03-30 | 2005-11-10 | Lambert James L | Diagnostic assays including multiplexed lateral flow immunoassays with quantum dots |
| DE102004023402A1 (de) * | 2004-05-12 | 2005-12-08 | Roche Diagnostics Gmbh | Verfahren zur Erhöhung des dynamischen Messbereichs von auf spezifischen Bindereaktionen basierenden, insbesondere immunologischen Testelementen |
| JP4805564B2 (ja) * | 2004-10-22 | 2011-11-02 | シスメックス株式会社 | 生体試料分析装置および方法 |
| US20080206782A1 (en) * | 2005-03-08 | 2008-08-28 | Genentech, Inc. | Methods for Determining the Bivalency of Protein and Antibody Therapeutics |
-
2006
- 2006-09-11 EP EP06019008A patent/EP1909206A1/de not_active Ceased
-
2007
- 2007-09-06 CA CA2600221A patent/CA2600221C/en not_active Expired - Fee Related
- 2007-09-10 JP JP2007234331A patent/JP4823178B2/ja active Active
- 2007-09-10 ES ES07017673.0T patent/ES2533467T3/es active Active
- 2007-09-11 US US11/853,100 patent/US20080070234A1/en not_active Abandoned
- 2007-09-11 CN CN200710148772XA patent/CN101144810B/zh active Active
-
2014
- 2014-07-14 US US14/330,179 patent/US9285376B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2600221A1 (en) | 2008-03-11 |
| ES2533467T3 (es) | 2015-04-10 |
| US20080070234A1 (en) | 2008-03-20 |
| CN101144810A (zh) | 2008-03-19 |
| JP2008070366A (ja) | 2008-03-27 |
| US20140322703A1 (en) | 2014-10-30 |
| JP4823178B2 (ja) | 2011-11-24 |
| CN101144810B (zh) | 2012-12-05 |
| EP1909206A1 (de) | 2008-04-09 |
| US9285376B2 (en) | 2016-03-15 |
| HK1118608A1 (en) | 2009-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9285376B2 (en) | Measuring range extension of chromatographic rapid tests | |
| JP6298043B2 (ja) | 自動分析計で流体試料中の被検体の量を測光法により決定するためのマルチアプリケーション法 | |
| US10101326B2 (en) | Method for determining a marker in small volume of a sample of a bodily fluid | |
| US20230194540A1 (en) | Digital microfluidics analytical techniques | |
| WO2013057135A1 (en) | Troponin and bnp based diagnosis of risk patients and cause of stroke | |
| Grabowska et al. | Multiplex electrochemical aptasensors for detection of endothelial dysfunction: Ready for prime time? | |
| CA2920066A1 (en) | Marker for statin treatment stratification in heart failure | |
| US11747328B2 (en) | Method for measuring the plasma concentration of an analyte directly on a whole blood sample | |
| HK1118608B (en) | Measuring range extension of chromatographic rapid tests | |
| JP5307141B2 (ja) | 心筋梗塞の早期予測因子としてのミオグロビン | |
| JP2010528306A (ja) | 心筋梗塞の早期予測因子としてのｈ−ｆａｂｐ | |
| WO2010009387A1 (en) | Methods for controlling protein loading variability in reverse phase protein microarrays | |
| Hedberg et al. | Analytical performance of time‐resolved fluorometry‐based Innotrac Aio!™ cardiac marker immunoassays | |
| RU2480772C1 (ru) | Способ одновременного детектирования тиротропина и общего тироксина в сухих пятнах крови | |
| KR101594379B1 (ko) | 면역크로마토그래피를 이용한 히스티딘-태그를 가진 단백질 검출방법 | |
| EP1909207B1 (de) | Messbereichserweiterung chromatografischer Schnellteste | |
| EP4086633A2 (en) | Prognostic method | |
| Swaanenburg | The biochemical and clinical assessment of cardiac markers for the detection of various forms of myocardial tissue damage | |
| WO2013017690A2 (en) | Troponin based rule in and rule out algorithm of myocardial infarction | |
| WO2014118539A1 (en) | Measuring solutions for an electrochemical detection system | |
| HK1177782A (en) | A method for determining a marker in small volume of a sample of a bodily fluid | |
| HK1225443B (zh) | 在心力衰竭中用於抑制素治疗分层的标记物 | |
| HK1119771B (en) | Devices and methods for diagnosing or predicting early stage cardiac dysfunctions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20190906 |